Akorn receives FDA approval for Ephedrine Sulfate Injection

LAKE FOREST - Generics pharmaceutical company Akorn has received approval from the U.S. Food and Drug Administration for its New Drug Application for Ephedrine Sulfate Injection.

Ephedrine sulfate injection is indicated for the treatment of clinically important hypotension occurring in the setting of anesthesia. The FDA's approval is for the drug's USP 50 mg/mL in 1 mL single dose ampule.